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Background: Obstructive sleep apnea (OSA) is associated with coronary artery disease (CAD). Intermittent hypoxia
associated with OSA increases sympathetic activity and may cause systemic inflammation, which may contribute to
CAD in patients with OSA. Treatment with continuous positive airway pressure (CPAP) has been shown to change
levels of inflammatory markers. We analyzed data from published studies by a systematic meta-analysis.
Objective: To asses if treatment for sleep apnea by CPAP will affect levels of inflammatory markers.
Data resources: PubMed, Embase and Cochrane library.
Methods: Study eligibility criteria full text English studies of adult, human subjects, addressing values of at least one
of the inflammatory markers before and after CPAP treatment. We used the definition of OSA as an apnea-hypopnea
index (AHI) of≥ 5/h, reported values in mean and standard deviation or median with range.
Participants: Adult, human.
Interventions: CPAP treatment for OSA.
Study appraisal and synthesis method: A total of 3835 studies were reviewed for inclusion, while 23 studies pooled
for analysis. A total of 14 studies with 771 patients were pooled for C-reactive protein (CRP); 9 studies with 209 patients
were pooled for tumor necrosis factor-alpha (TNF-α); and 8 studies with 165 patients were pooled for interleukin-6 (IL-6).
Endpoint definitions: The following inflammatory markers were chosen: CRP, TNF-α, and IL-6.
Results: C-reactive protein: Study level means ranged from 0.18 to 0.85 mg/dl before CPAP treatment and 0.10 to
0.72 mg/dl after CPAP treatment. Mean differences, at a study level, ranged from −0.05 to 0.50. The pooled mean
difference was 0.14 [95% confidence interval 0.08 to 0.20, p < 0.00001]. There was heterogeneity in this endpoint (df = 13,
p < 0.00001, I2 = 95%).
Tumor necrosis factor-α: Study level means ranged from 1.40 to 50.24 pg/ml before CPAP treatment and 1.80 to
28.63 pg/ml after CPAP treatment. Mean differences, at a study level, ranged from −1.23 to 21.61. The pooled mean
difference was 1.14 [95% confidence interval 0.12 to 2.15, p = 0.03]. There was heterogeneity in this endpoint (df = 8,
p < 0.00001, I2 = 89%).
Interleukin-6: Study level means ranged from 1.2 to 131.66 pg/ml before CPAP treatment and 0.45 to 66.04 pg/ml
after CPAP treatment. Mean differences, at a study level, ranged from −0.40 to 65.62. The pooled mean difference
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was 1.01 [95% confidence interval −0.00 to 2.03, p = 0.05]. There was heterogeneity in this endpoint (df = 7,
p < 0.00001, I2 = 95%).
Limitations: Only published data. Studies pooled were mainly small, non-randomized trials.
Conclusion: Sleep apnea treatment with CPAP improves levels of inflammatory markers.
Keywords: OSA (obstructive sleep apnea), CPAP (continuous positive airway pressure), CRP (C-reactive
protein), TNF-α (tumor necrosis factor-alpha), IL-6 (interleukin-6), AHI (apnea-hypopnea index), ODI (oxygen
desaturation index), BMI (body mass index)Introduction
Obstructive sleep apnea (OSA) is a common disorder
affecting about 4% of middle-aged males and 2% of
middle-aged females in the developed world [1] and is a
significant source of morbidity and mortality [2]. OSA is
characterized by recurrent episodes of upper airway col-
lapses during sleep. These recurrent episodes of upper
airway collapse usually are accompanied by oxyhemo-
globin desaturation and terminated by brief arousals
which result in marked sleep fragmentation and chronic
excessive daytime sleepiness (EDS) [1,3]. As a result,
there is an increased expression of systemic inflamma-
tory markers, a sustained activation of the sympathetic
nervous system [4], and derangement in endothelial
function [5]. Many of these physiologic and biochemical
abnormalities are implicated in the pathogenesis of car-
diovascular and cerebrovascular diseases, as ongoing
inflammatory responses play important roles in athero-
sclerosis [6,7]. OSA has been increasingly linked to cardio-
vascular and cerebrovascular disease [8,9] and many
studies have shown that OSA is associated with increased
cardiovascular and cerebrovascular morbidity [10-14].
The literature suggests that an inflammatory etiology,
in addition to mechanical factors, may contribute to
the pathogenesis of OSA, as surgical biopsies of the
uvula in patients with OSA have demonstrated histo-
logical abnormalities, including subepithelial edema and
excessive inflammatory cell infiltration [15,16]. Also, the
overexpression of interleukin-8 (IL-8) in human bronchial
epithelial cells in response to a vibratory stimulus gener-
ated by snoring has been implicated to the pathogenesis
of OSA [17]. Many studies have reported that patients
with OSA have increased levels of mediators of the
systemic inflammatory response, including cell adhe-
sion molecules (ICAM), coagulation factors (Factor VIII,
Tissue factor), and C-reactive protein (CRP) [18-20]. Pro-
inflammatory cytokines are also up-regulated in patients
with OSA [21-23]. In particular, significant elevations
in serum levels of tumor necrosis factor-α (TNF-α),
interleukin-1β (IL-1β), and interleukin-6 (IL-6) have
been seen in patients with OSA [18,24-29]. However,
some studies did not show elevation of CRP in pa-
tients with OSA [30,31].CRP is an important serum marker of inflammation.
It is synthesized from the liver and is largely under the
regulation of the pro-inflammatory cytokine IL-6 [32-34].
IL-6 is believed to represent the major regulator of the
hepatic acute phase response [33,34]. Unlike cytokines,
CRP levels are quite stable in the same individual
across 24 hours and may reflect the level of inflamma-
tory response [35].
CRP may play a direct role in the initiation and progres-
sion of atherosclerosis [36]. Its pro-inflammatory and pro-
atherogenic properties have been found in endothelial cells
[37], vascular smooth muscle cells [38], and monocyte-
macrophages [39]. CRP levels are also associated with oxi-
dative stress [40]. Epidemiological studies have shown that
an elevated CRP level in the high-normal (0.2 to 1.5 mg/dl)
range in apparently healthy men and women is a strong
predictor of cardiovascular risk [41-43]. In patients with
acute coronary artery disease, stable angina pectoris, and a
history of myocardial infarction, higher levels of CRP are
also associated with future cardiovascular events [44,45].
IL-6 is a circulating cytokine known to be secreted
from a number of different cells, including activated
macrophages and lymphocytes [46]. Inflammation is the
main stimulus for IL-6 production, but other stimuli also
exist, such as cigarette smoke [46] and adiposity [47].
TNF-α is a pro-inflammatory cytokine that has a sig-
nificant role in host defense and also mediates the
pathogenesis of a number of disease processes, including
atherosclerosis, septic shock, and auto-immune disor-
ders [48]. TNF-α has two transmembrane-bound recep-
tors and soluble forms that are released by proteolysis
of the cell-bound receptor under the control of other
inflammatory cytokines (e.g., IL-6, IL-2, IFN-γ), T cell
activation, and by TNF-.alpha; itself [48,49].
Hypoxemia results in increases in IL-6 and CRP in nor-
mal humans [50]. Sleep fragmentation and deprivation
also induces an increase in cytokines that may underlie
inflammatory responses, which lead to cardiovascular
morbidity [20,30]. OSA results in repetitive and severe
nocturnal hypoxemia and sleep disturbances [1,3,51].
Continuous positive airway pressure (CPAP) is the
primary treatment for OSA [52], since it eliminates
upper airway collapse during sleep and improves sleep
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life [54]. Evidence shows that CPAP therapy reduces
cardiovascular morbidity and risk [11,55], There are
many studies with small sample sizes and few with
larger sample sizes which address the effect of CPAP
therapy on cardiovascular profiles and serum inflam-
matory markers. Therefore, we performed a meta-
analysis to study the effects of CPAP on the serum
inflammatory markers CRP, IL-6, and TNF-α.Objectives
We aim to assess the effect of CPAP treatment on
inflammatory markers in human subjects with sleep
apnea by comparing levels of inflammatory markers
before and after specified treatment in all available
published studies.Methods
Studies and endpoint definitions
PRISMA guidelines were followed to perform this meta-
analysis. PICOS format was followed; P: inflammatory
markers (CRP, TNF-α, and IL-6), I: CPAP treatment, C;
levels of markers before and after treatment period, O:
decrease in marker levels. Inflammatory markers were
chosen based on a review of the literature. The following
inflammatory markers were chosen: CRP, TNF-α, and
IL-6. Inclusion criteria for the subsequent study selec-
tion were as follows: 1) the study must have been in
English; 2) full text manuscripts had to be available;
3) the study must have reported values for at least
one of the markers of interest, both before and after
CPAP treatment (4 weeks to 12 months after begin-
ning treatment); 4) OSA was strictly defined as AHI
of ≥ 5/h measured by polysomnography; 5) the study
must have reported values in mean and standard deviation
or median with range; 6) the patient number for all groupsTable 1 Quality of evidence: number and level of evidence of
Hierarchy of
Level of evidence Descr
1 a Systemic review (with homogeneity*) of r
1 b Individual randomized controlled clinical tr
1 c All or none
2 a Systemic review (with hom
2 b Individual cohort study (including lo
2 c “Outcomes” Researc
3 a Systemic review (with homoge
3 b Individual Case
4 Case-series (and poor quality c
5 Expert opinion without explicit critical appraisal, or ba
Others Letters to edmust have been reported; 7) the study must have been
performed on adult (>18 years of age) humans.
Data source and study selection
Studies for review were found by searching the PubMed
and Cochrane databases with a duration from January 01,
1960 to December 31st, 2011. Embase was also searched
with the same criteria in order to identify additional stud-
ies. Unpublished data from scientific meetings were not
searched, since most abstracts do not provide enough data
needed for meta-analyses. Searches were conducted using
different combinations of the following key words: sleep
apnea, inflammatory markers, C-reactive protein, tumor
necrosis factor-α, interleukin-6, continuous positive airway
pressure, autoadjusting positive airway pressure, and pres-
sure therapy. In order to ensure that relevant sources
were not left out, each marker or therapy was searched
in its abbreviated form using the same word combinations
as before. Multiple authors individually searched for
and scored manuscripts for inclusion. Manuscripts were
scored in duplicates, and if a manuscript was scored
differently by two authors, then that manuscript was
reviewed by a third author to finalize inclusion. The
quality of studies was ranked according to the Sackett
et al’s hierarchy of evidence [56] (Table 1).
Data extraction and statistical analysis
Data was extracted from each study by a single author
and then reviewed by a second author to ensure that no
errors were made. Serum levels of inflammatory markers
before and after CPAP treatment were extracted from
studies as the mean with standard deviation. For studies
in which data was reported in median and interquartile
range, mean and standard deviation were calculated util-
izing methods described by Hozo et al. [57].
Only our target variables (inflammatory markers) were
recorded since we did not plan to do subgroup analysespeer-reviewed and published papers
evidence
iption No. of studies
andomized, controlled clinical trials (RCTs) 0
ial (RCT) (with narrow Confidence Interval‡) 0
case series 0
ogeneity*) of cohort studies 0
w quality RCT; e.g., <80% follow-up) 0
h; Ecological studies 0
neity*) of case–control studies 0
–control Study 23
ohort and case–control studies) 0
sed on physiology, bench research or “first principles” 0
itor, Abstract 0
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were included in our review. If studies included data
from both CPAP and APAP treatment, the each set of
data was included in the meta-analysis as a separate
study. For example, Patruno et al. [58] utilized both
CPAP and APAP treatments. If a study involved the
removal CPAP and its effects on inflammatory markers,
we excluded the study from our meta-analysis. For
example, Phillips et al. [59] measured the effect of
short-term withdrawal from CPAP on levels of vascular
inflammatory markers. The risk for bias was assessed at a
study level and an outcome level. To minimize the effect
of bias by including non-compliant patients, we only
included compliant patients, utilizing a compliance
definition of CPAP usage ≥ 4 hours on at least 70% of
nights when reported by the manuscript. We also ex-
cluded the studies if OSA was not diagnosed by mea-
sured by polysomnography. For example Kohler 2009
was excluded since OSA was defined by Oxygen De-
saturation Index instead of AHI. Some studies that
fulfilled our inclusion criteria had to be excluded be-
cause values of inflammatory markers were exponen-
tially larger than the values for the same inflammatory
marker in all other studies. Tamaki et al. [60], for
example, measured the production of TNF-α by mono-
cytes before and after treatment with CPAP, and the
values, when converted, were 1000 times greater than
the other studies measuring TNF-α levels. Intercellular
adhesion molecule (ICAM) and interleukin-8 (IL-8)
were not included in this meta-analysis because there
were not enough studies available to performed meta-
analysis. Moreover oxyhemoglobin desaturation data
was not included for the same reason. For studies inScreening with key words – 3835 stud
Applied for detailed evaluation – 1210 stu
Evaluation of full text studies – 65 stud









Figure 1 Study selection methodology.which no numerical data accompanied the graphical
data, the authors were contacted in order to obtain
the data. Authors of one study produced two inde-
pendent papers that included the same CPAP and in-
flammatory markers data, so we only included the
data from Schiza et al. 2010 [61] and not from
Mermigkis et al. 2011 [62].
Statistical analyses were done using RevMan software
version 5. Pooled mean difference was calculated using
a random effects model for all outcomes due to the
high level of heterogeneity present. Heterogeneity was
assessed by calculating the Cochrane Q statistic. I2 statis-
tics were also calculated to help quantify the amount
of heterogeneity. An I2 of the following percentages
represents different levels of heterogeneity: 25-49%
low, 50-74% moderate, and 75-100% high. Measure-
ment units of inflammatory markers we used in the
meta-analysis were mg/dl for CRP and pg/ml for IL-6
and TNF-α. If values of any of these markers were not
reported in the same standard measurement unit we
used, the values were converted to the appropriate
unit. Primary principal measures were differences in
means of inflammatory markers before and after CPAP
treatment.Results
A total of 3835 studies were reviewed for inclusion with
23 studies pooled for analysis. The quality of evidence
was low (3B-individual case–control study) for all 23
studies. A total of 14 studies with 771 patients were
pooled for CRP; 9 studies with 209 patients were pooled
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Table 2 Selected studies measuring serum CRP before and after CPAP
Study Study design Study population characteristics OSA definition Minimum CPAP usage Outcome
Carniero et al. 2009 [63] Case–control 7 severely obese men AHI > 30 ≥ 5 h/day for 3 months No significant change
Chung et al. 2011 [64] Case–control 25 total: 22 men, 3 women AHI ≥15 ≥ 4 h/day for 3 months No significant change
Colish et al. 2012 [65] Case–control 47 total: 32 men, 15 women; 25 obese, 22 overweight AHI≥ 15 ≥ 4.5 h/day for 12 months No significant change
Dorkova et al. 2008 [66] Case–control 16 total: 15 men, 1 woman AHI≥ 30 ≥ 4 h/day for 8 weeks No significant change
Harsch et al. 2004 [67] Case–control 20 obese patients AHI = 48.6 ± 9.1
(mean ± SD)
5.32 ± 0.67 h/day
(mean ± SD) for 8 weeks
No significant change
Iesato et al. 2007 [68] Case–control 36 total AHI≥ 20 ≥ 4 h/day for 3 months Significantly decreased
Ishida et al. 2009 [69] Case–control 40 total: 32 men, 8 women AHI > 20 > 4 h/day, 5d/week for 6 months Significantly decreased
Patruno et al. 2007 [58] (APAP) Case–control 15 total AHI > 20 > 4 h/day for 3 months Significantly decreased
Patruno et al. 2007 [58] (CPAP) Case–control 16 total AHI > 20 > 4 h/day for 3 months Significantly decreased
Ryan et al. 2007 [70] Case–control 49 total AHI > 15 > 4 h/day for 6 weeks No significant change
Schiza et al. 2010 [61] Case–control 436 total: 252 men, 184 women AHI > 15 > 4 h/day, 5d/week for 12 months Significantly decreased
Steiropoulos et al. 2007 [71] Case–control 20 total: 16 men, 4 women AHI > 15 ≥ 4 h/night for 6 months Significantly decreased
Yokoe et al. 2003 [18] Case–control 17 total AHI≥ 20 1 month Significantly decreased



















Table 3 Selected studies measuring serum TNF-α before and after CPAP
Study Study design Study population
characteristics
OSA definition Minimum CPAP usage Outcome
Arias et al. 2008 [73] Cross-over 25 men AHI≥ 10 ≥ 3.5 h/day for 3 months No significant change
Carniero et al. 2009 [63] Case–control 7 severely obese men AHI > 30 ≥ 5 h/day for 3 months Decreased, not significant
Guasti et al. 2009 [74] Case–control 16 total AHI > 20 Good compliance for 12 weeks No significant change
Minoguchi et al. 2004 [25] Case–control 12 total AHI≥ 20 > 4.5 h/day for 1 month Significantly decreased
Ryan et al. 2005 [75] Case–control 19 total AHI≥ 20 4.4 h/day (mean) for 6 weeks Significantly decreased
Ryan et al. 2006 [76] Case–control 49 men AHI > 5 Compliant for 6 weeks Significantly decreased
Steiropoulos et al. 2009 [77] Case–control 32 total AHI > 5 ≥ 4 h/day for 6 months Significantly decreased
Tamaki et al. 2009 [60] Case–control 33 total: 30 males,
3 females
AHI≥ 10 3 months (no compliance data) Significantly decreased
Vgontzas et al. 2008 [78] Case–control 16 total AHI > 5 ≥ 4 h/day, ≥ 5d/week for 3 months No significant change
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inflammatory markers are outlined in Tables 2, 3 and 4.
C-reactive protein
With respect to CRP, study level means ranged from
0.18 to 0.85 mg/dl before CPAP treatment and 0.10 to
0.72 mg/dl after CPAP treatment. Mean differences, at a
study level, ranged from −0.05 to 0.50. The pooled mean
difference was 0.14 [95% confidence interval 0.08 to
0.20, p < 0.00001]. There was heterogeneity in this end-
point (df = 13, p < 0.00001, I2 = 95%) (Figure 2).
Tumor necrosis factor-α
With respect to TNF-α, study level means ranged from
1.40 to 50.24 pg/ml before CPAP treatment to 1.80 to
28.63 pg/ml after CPAP treatment. Mean differences, at
a study level, ranged from −1.23 to 21.61. The pooled
mean difference was 1.14 [95% confidence interval 0.12
to 2.15, p = 0.03]. There was heterogeneity in this end-
point (df = 8, p < 0.00001, I2 = 89%) (Figure 3).
Interleukin-6
Study level means ranged from 1.2 to 131.66 pg/ml
before CPAP treatment and 0.45 to 66.04 pg/ml after
CPAP treatment. Mean differences, at a study level,Table 4 Selected studies measuring serum IL-6 before and aft
Study Study design Study population
characteristics
OSA
Arias et al. 2008 [73] Cross-over 25 men A
Burioka et al. 2008 [79] Case–control 9 total A
Carniero et al. 2009 [63] Case–control 7 severely obese men A
Ryan et al. 2006 [76] Case–control 49 men A
Steiropoulos et al. 2009 [77] Case–control 32 total A
Vgontzas et al. 2008 [78] Case–control 16 total A
Ye et al. 2010 [80] Case–control 10 total A
Yokoe et al. 2003 [18] Case–control 17 total Aranged from −0.40 to 65.62. The pooled mean differ-
ence was 1.01 [95% confidence interval 0.00 to 2.03,
p = 0.05]. There was heterogeneity in this endpoint (df = 7,
p < 0.00001, I2 = 95%) (Figure 4).
Discussion
The present meta-analysis showed that CPAP therapy
improves serum levels of the inflammatory markers CRP,
TNF-α, and IL-6. Using a p-value of <0.05 to mark a
significant change, the levels of CRP and TNF-α were
significantly decreased, whereas the levels of IL-6
showed no significant change. IL-6 levels did, however,
show a general trend of decreasing values with CPAP
usage.
With respect to CRP, the following studies agreed
that CPAP usage significantly decreases serum levels
of CRP: Iesato et al. 2007 [68], Ishida et al. 2009 [69],
Patruno et al. 2007 [58], Schiza et al. 2010 [61],
Steiropoulos et al. 2007 [71], Yokoe et al. 2003 [18],
and Zhao et al. 2011 [72]. With respect to TNF-α, the
following studies agreed that CPAP usage significantly
decreases serum levels of TNF-α: Minoguchi et al. 2004
[25], Ryan et al. 2005 [75], Ryan et al. 2006 [76],
Steiropoulos et al. 2009 [77], and Tamaki et al. 2006 [60].
With respect to IL-6, the following studies agreed thater CPAP
definition Minimum CPAP usage Outcome
HI≥ 10 ≥ 3.5 h/day for 3 months No significant change
HI > 30 5 h/day (mean) for 3 months Significantly decreased
HI > 30 ≥ 5 h/day for 3 months No significant change
HI > 5 Compliant for 6 weeks No significant change
HI > 5 ≥ 4 h/day for 6 months No significant change
HI > 5 ≥ 4 h/day, ≥ 5d/week for 3 months No significant change
HI≥ 20 > 4 h/day for 6 months Significantly decreased
HI≥ 20 1 month Significantly decreased
Study or Subgroup
Carneiro et al 2009
Chung et al 2011
Colish et al 2012
Dorkova et al 2008
Harsch et al 2004
Iesato et al 2007
Ishida et al 2009
Patruno et al 2007 APAP
Patruno et al 2007 CPAP
Ryan et al 2007
Schiza et al 2010
Steiropoulos et al 2007
Yokoe et al 2003
Zhao et al 2011
Total (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 273.64, df = 13 (P < 0.00001); I² = 95%





























































































































CRP before CPAP CRP after CPAP Mean Difference Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Lower level without CPAP Lower level with CPAP
Figure 2 CRP levels before and after CPAP treatment.
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IL-6: Burioka et al. 2008 [79], Ye et al. 2010 [80],
and Yokoe et al. 2003 [18].
We also examined why some studies did not agree
with our overall finding that CPAP significantly improves
levels of inflammatory markers. With regards to CRP,
Carniero et al. 2009 [63] showed there was no significant
change in the levels of CRP after CPAP, and this could
possibly be due to the small sample population (7 sub-
jects) of the study. Chung et al. 2011 [64], Dorkova et al.
2008 [66], Harsch et al. 2004 [67], and Ryan and col-
leagues [70] showed no significant change in serum CRP
levels, possibly because of the small sample populations
(25, 16, and 20, respectively) and possibly because there
was no significant weight reduction among the patients
in the study. There is some debate on whether CRP
levels are dependent on obesity or the severity of OSA
[31,81]. Kohler and colleagues [82] performed a ran-
domized controlled trial and similarly concluded that
4 weeks of CPAP had no significant reduction in CRP
levels, possibly due to the fact that many of the sub-
jects also had a number of other comorbidities in
addition to OSA.Figure 3 TNF-α levels before and after CPAP treatment.Five of the nine studies measuring TNF-α levels
showed that CPAP usage significantly decreases serum
levels of TNF-α [25,60,75-77]. Studies that showed no
significant change in TNF-α were examined to deter-
mine why those studies did not agree with our overall
findings. Carniero et al. 2009 [63] had a very small
sample population (7) and showed that CPAP usage
over 3 months decreases serum TNF-α, though not
significantly. Guasti et al. 2009 [74] also had a small
sample population (only 16) and many of the patients
had other comorbidities, such as elevated BMI. In
addition to a small sample population (16) and patients
having high BMIs, Vgontzas and colleagues [78] noted that
there were discrepancies in the compliance of the patients
using CPAP. Only 10 of the patients used CPAP for
more than 4 hours per night.
With respect to IL-6, only three of nine studies
showed that CPAP usage decreases serum levels of IL-6
[18,79,80]. The rest of studies examined showed no sig-
nificant change in serum IL-6 after CPAP treatment.
Again, these studies all had populations under 50 people,
and the patients also exhibited comorbidities, like obes-
ity. A few of these studies [18,76,82] only measured the
Study or Subgroup
Arias et al 2008
Burioka et al 2008
Carneiro et al 2009
Ryan et al 2006
Steiropoulos et al 2009
Vgontzas et al 2008
Ye et al 2010
Yokoe et al 2003
Total (95% CI)
Heterogeneity: Tau² = 1.48; Chi² = 133.68, df = 7 (P < 0.00001); I² = 95%













































































IL-6 before CPAP IL-6 after CPAP Mean Difference Mean Difference
IV, Random, 95% CI
-50 -25 0 25 50
Lower level without CPAP Lower level with CPAP
Figure 4 IL-6 levels before and after CPAP treatment.
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which is relatively short compared to many of the other
studies examined.
There are a few limitations of this meta-analysis. It is
very clear that the available literature is largely low-level
evidence. Most of the studies included in the meta-
analysis have examined the confounding factors (age,
AHI, BMI), which we did not adjust, since we did not
perform a meta-regression analysis. Moreover we did
not perform the subgroups analysis to examine effect of
severity of OSA on inflammatory markers before or
after treatment. There are number of studies available
in which levels of these markers were measured in
patients with OSA and controls. Those studies cannot
be included because of significant methodological dif-
ferences (no CPAP). We performed a metaregression
analysis on this larger pool of studies (submitted to
JCSM being reviewed). Also, we did not account for
CPAP compliance rates. If we had included the data
from non-compliant CPAP groups, the serum levels
of the selected inflammatory markers may have been
affected. Another potential limitation is that we ex-
cluded all papers written in languages other than
English, which could raise the possibility of publica-
tion bias. We have excluded some studies with expo-
nentially high values when compared to the other
studies in this meta-analysis. Including those studies
could affect the net result of the meta-analysis. We
were not able to retrieve the numerical data from some
studies that reported data only in graphical form. That
data inclusion could have affected the results of our
meta-analysis. It is known that studies with positive
results tend to get published while studies with nega-
tive results are less likely to be published, and we only
included data from published studies in our meta-
analysis. This could have led to publication bias as well.
Despite all these variations, it was reassuring that in
majority of the studies (regardless of the composition
of the study) those with CPAP treatment have lower
levels of systemic inflammatory markers. This suggests
that selection and sampling biases were unlikely to beresponsible for the observed associations. The improve-
ment in inflammatory markers suggests that OSA treat-
ment modulates the cardiovascular risk profile through
multiple mechanisms, including inflammation, which
may play an important role for the development of
atherosclerosis. Further studies are required to explore
this dimension of the cardiovascular risk profile, such
as the impact of OSA treatment on atherosclerosis
and vasculopathy.
In conclusion, CPAP usage for patients with OSA sig-
nificantly decreases serum inflammatory markers CRP
and TNF-α. Also, CPAP usage seems to decrease serum
levels of IL-6.
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